‹ ›
MYP_023584
← PREVIOUS NEXT → BACK
Basic Information
EK1V1
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Standard
37 amino acids
C202H329N45O65S
Standard
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELK
Physicochemical Analysis
4460.10 Da
4.53
-4.52
-4.76
-0.1223
-0.53
0.75
-0.09
20.09
115.95
0.0811
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1827.37
-10.36
61.0
62.0
162.0
313.0
3.0
38.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0287631 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells
2.672±0.3845 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0321770 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 | protein-mediated cell; -cell
0.2735±0.0041 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0326656 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
inhibition of SARS-CoV-2 pseudovirus infection in Huh-7 cells
2.6721±0.3845 μM
IC50
PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0331473 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of pseudovirus infection in Huh-7 cells
1.791±0.3632 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0336369 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | Huh-7 cells
4.37±0.7197 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
FIRST PREV 1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 3 of 4